Tag : MULTIPLE SCLEROSIS

The phase 3 HERCULES trial demonstrates that tolebrutinib reduces disability progression in non-relapsing secondary progressive multiple sclerosis (nrSPMS) by 31%, offering hope for this underserved population.

Multiple sclerosis (MS) is among the most common central nervous system (CNS) inflammatory demyelinating diseases with an estimated global prevalence of 1 in 3,000 people in 2020. Although MS is regarded as relatively uncommon in the Asia Pacific Region and even rarer in Hong Kong with a local prevalence of 0.77 per 100,000 people in 1999, a recent study revealed that the local MS prevalence was 6.9 per 100,000 people in 2020, which was higher than mainland China and Taiwan. In an interview with Omnihealth Practice, Dr. Alexander Lau explained the rising trend of MS in Hong Kong over the past decade. To better manage MS, Dr. Lau also discussed the opportunity of having an integrative platform that combines both Western and Chinese medicine as a comprehensive approach for long-term MS treatment.